Patients with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer experienced a 58% reduction in the risk of disease progression or death when ...

Patients with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer experienced a 58% reduction in the risk of disease progression or death when treated with atezolizumab plus modified FOLFOX6 and bevacizumab compared with atezolizumab alone, according to results from the NRG-GI004/SWOG S1610 COMMIT trial published recently in the Journal of Clinical Oncology.